Tag: GBM

Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is lending its support to Glioblastoma (GBM) Awareness Day 2022 and remains firmly focused on developing a treatment that may help improve the […]

DelveInsight’s ‘Glioblastoma Multiforme (GBM) Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and […]